Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome. That's welcome news.

While most recover, early treatment is critical. Preventive measures focus on infection control and maintaining overall health. Guillain-Barré Syndrome (GBS) is a rare but serious neurological ...

Guillain-Barré syndrome (GBS ... or plasma exchange (PE) are the first-line treatments in addition to management of ventilatory failure. IVIg is more widely used than PE due to its ease of ...

Financially, Annexon has a strong cash position, providing a runway of 5-8 quarters, but the stock trades almost at cash due to market skepticism. Risks include the ex-US trial locations for GBS and ...

Feb. 28, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International today released new survey data illustrating how people with Guillain-Barré ... after treatment. Financial, social, and ...

Genzyme Corp. (Sanofi Genzyme) has divulged emopamil-binding protein (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, transverse myelitis, neuromyelitis optica, optic ...

Bhubaneswar: Odisha recorded its first suspected death from Guillain-Barré Syndrome (GBS), a rare neurological disorder, ...

A teenager left paralysed by Guillain-Barré syndrome after a bout of food poisoning has been denied ACC cover after a third ...

Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long ...